Ocugen has made significant strides in the realm of gene therapy by announcing the positive outcomes of its phase 1 GARDian1 trial for OCU410ST, specifically targeting Stargardt disease. This groundbreaking research emphasizes the potential of gene therapy as a transformative approach in treating this retinal condition.
Gene Therapy Overview
OCU410ST employs an adeno-associated virus (AAV) delivery system designed for the retinal administration of the RORA gene. This gene plays a crucial role in regulating various pathophysiological pathways associated with Stargardt disease, including oxidative stress, inflammation, and cell survival mechanisms.
Key Trial Results
The results from the GARDian1 trial were recently published in a peer-reviewed journal, highlighting the effectiveness of OCU410ST. Dr. Huma Qamar, Ocugen’s Chief Medical Officer, expressed optimism regarding the findings. She noted that the trial demonstrated both functional and structural improvements, marking a shift from traditional treatment methods. The results suggest that OCU410ST may serve as a one-time gene therapy solution that benefits a broad range of patients, regardless of their specific genetic mutations.
In this trial, nine participants with Stargardt disease were treated with OCU410ST. Among those, eight completed the 12-month follow-up. Data revealed that in six patients with suitable imaging, there was a significant reduction in atrophic lesion growth—54% less in treated eyes compared to untreated ones. Additionally, lesion expansion was observed to be 50% slower in the treated group.
Visual Acuity Improvements
The improvements in best corrected visual acuity (BCVA) were equally noteworthy. Out of six evaluable patients, those who received OCU410ST exhibited an average gain of 6 letters in BCVA, while untreated eyes showed a decline. These findings underscore the potential of OCU410ST to enhance visual function effectively.
Future Clinical Trials
Encouraged by these promising results, Ocugen is advancing to the phase 2/3 GARDian3 trial, which aims to enroll 51 participants diagnosed with Stargardt disease. This upcoming trial will focus on administering a single subretinal injection of OCU410ST to 34 participants, with the remaining 17 serving as a control group. The primary goal is to assess the reduction in atrophic lesion size, while secondary endpoints will explore improvements in both BCVA and low luminance visual acuity.
Regulatory Progress
Ocugen’s regulatory ambitions are aligning with its clinical goals. In June 2025, the FDA granted clearance for the Investigational New Drug (IND) amendment, facilitating the next phase of trials. The company anticipates completing enrollment for the GARDian3 trial by the first quarter of 2026, with plans to file a Biologics License Application (BLA) in the first half of 2027.
Takeaways
- OCU410ST represents a novel approach to treating Stargardt disease through gene therapy.
- The phase 1 GARDian1 trial demonstrated significant reductions in lesion growth and improvements in visual acuity.
-
Future trials will further investigate the efficacy and safety of OCU410ST in a larger patient population.
-
Ocugen is on track to file a BLA, marking a critical step toward bringing this innovative therapy to market.
Conclusion
The progress made in the GARDian1 trial signifies a remarkable leap forward in the treatment of Stargardt disease. With promising data and a clear path toward further clinical evaluation, OCU410ST could redefine the therapeutic landscape for patients affected by this condition. As research continues, the potential for a transformative impact on patient lives grows increasingly tangible.
Read more → www.ophthalmologytimes.com